Arena Pharmaceuticals Profit Margin 2006-2021 | ARNA
Current and historical gross margin, operating margin and net profit margin for Arena Pharmaceuticals (ARNA) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Arena Pharmaceuticals net profit margin as of June 30, 2021 is 0%.
|Arena Pharmaceuticals Annual Profit Margins
|Arena Pharmaceuticals Quarterly Profit Margins
||Medical - Biomedical and Genetics
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration, or FDA, for marketing in the United States, and was made available by prescription in June 2013 to adults who are overweight with a comorbidity or obese. They are exploring BELVIQ for possible new indications, using different formulations, and in combination with other drugs.